Trial reportFrontiers in immunology2020
CCR4
Trial report in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Immunogenetics in psoriasis: towards personalised diagnosis and treatment strategies.Genes and immunity · 2026Review
- Gene expression profiling of recipient immune cells induced by 7 × 19 CAR-T cell dosing in a syngeneic mouse model.PloS one · 2026Article
- Microneedle-Mediated Transdermal Drug Delivery for the Treatment of Multiple Skin Diseases.Pharmaceutics · 2025Review
- Macrophages foster anti-tumor immunity by ZEB1-dependent cytotoxic T cell chemoattraction.Communications biology · 2025Article
- Single-cell transcriptomics of melanoma sentinel lymph nodes identifies immune cell signatures associated with metastasis.JCI insight · 2025Article
- Circulating CD8 T cells from patients with mild-to-moderate psoriasis are functionally impaired.Frontiers in immunology · 2025Article
- T cell trafficking in human chronic inflammatory diseases.iScience · 2024Review
- From PsO to PsA: the role of TFrontiers in medicine · 2024Review
- From the Skin to Distant Sites: T Cells in Psoriatic Disease.International journal of molecular sciences · 2023Review
- Functional heterogeneity of human skin-resident memory T cells in health and disease.Immunological reviews · 2023Review
- LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.Cancer immunology research · 2023Article
- Could Targeted Pharmacotherapies Exert a "Disease Modification Effect" in Patients with Chronic Plaque Psoriasis?International journal of molecular sciences · 2022Review
- Article
- The biological basis of disease recurrence in psoriasis: a historical perspective and current models.The British journal of dermatology · 2022Review
- FoxP3Frontiers in immunology · 2022Article
- CD8Frontiers in immunology · 2022Review
- Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates DiagnosisFrontiers in immunology · 2022Article
- Bath Psoralen Plus UVA Therapy Suppresses Keratinocyte-Derived Chemokines in Pathogenetically Relevant Cells.JID innovations : skin science from molecules to population health · 2021Article
- Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments.Molecular biology reports · 2021Article
- Increased Dysfunctional and Plastic Regulatory T Cells in Idiopathic Orbital Inflammation.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine receptor CCR4 has emerged as a skin-homing molecule important for the migration of T cells from the blood to the dermis. From our previous data on psoriasis patients, CCR4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.